Vice President, FibroGen Inc.
Dr Rahul Rajan Kaushik is currently at FibroGen, Inc. where he is Vice President and Head of Antibody/Protein process development and manufacturing. Prior to this he was the Executive Director and Head of external manufacturing at Nektar Therapeutics where he led CMC aspects including technology transfer, GMP manufacturing, process characterization and process validation of Bempegaldesleukin, a PEGylated conjugate of IL-2. Rahul spent over 15 years at Amgen, Inc. where he adopted several leadership roles within CMC ranging from formulation development, analytical development, process development, technology transfer, process characterization and PPQ oversight.
Rahul enabled pharmaceutical development and regulatory approval for Repatha®, Riabni®, Amovig® and Amgevita® and contributed to CMC development of several antibodies into Phase 1 and commercial franchises including Kyprolis® and Imlygic®. He also established external partnerships for product development and clinical manufacturing, in addition to leading the team that established an end-to-end, state of the art pilot facility. He has led cross-functional teams delivering significant outcomes in lifecycle management initiatives related to patient centric product presentations, especially in the area of oncology. He holds an undergraduate degree in Chemistry from I.I.T. Bombay, first in graduating class and in the top 20 out of >100,000 applicants. Following this, he obtained a full scholarship to pursue a Ph.D. at Stanford University, which he completed in the field of cell biology, furthering our understanding of the Ubiquitin Proteasome pathway which is implicated in oncology and neurodegenerative disorders.